A novel immunotherapy — the history of CAR T-cell therapy

Wrona, Ewa; Potemski, Piotr

doi:10.5603/ocp.2019.0016

Cited by 4 publications

(2 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the first studies ended up with disappointment, today, the other genetically modified T cell is chimeric antigen receptors, CAR. Many studies are conducted around the world on CAR-T technology and it is believed that positive results will be achieved in the near future [29,30].…”

Section: Adoptive Cell Therapymentioning

confidence: 99%

Immune System Modulations in Cancer Treatment: Nanoparticles in Immunotherapy

Kızılbey¹,

Türkoğlu²,

Kırmızıtaş³

2021

Cell Interaction - Molecular and Immunological Basis for Disease Management

View full text Add to dashboard Cite

Cancer immunotherapy is based on the idea of overcoming the main problems in the traditional cancer treatments and enhancing the patient’s long-term survival and quality of life. Immunotherapy methods aimed to influence the immune system, to detect and eradicate the tumors site and predict the potential results. Nowadays, nanomaterials-based immunotherapy approaches are gaining interest due to numerous advantages like their ability to target cells and tissues directly and reduce the off-target toxicity. Therefore, topics about immune system components, nanomaterials, their usage in immunotherapy and the benefits they provide will be discussed in this presented book chapter. Immunotherapy can be divided into two groups mainly; active and passive immunotherapy including their subtitles such as immune checkpoint inhibitors, adoptive immunotherapy, CAR-T therapies, vaccines, and monoclonal antibodies. Main classification and the methods will be evaluated. Furthermore, state-of-art nanocarriers based immunotherapy methods will be mentioned in detail. The terms of size, charge, material type and surface modifications of the nanoparticles will be reviewed to understand the interference of immune system and nanoparticles and their advantages/disadvantages in immunotherapy systems.

show abstract

Section: Adoptive Cell Therapymentioning

confidence: 99%

Immune System Modulations in Cancer Treatment: Nanoparticles in Immunotherapy

Kızılbey¹,

Türkoğlu²,

Kırmızıtaş³

2021

Cell Interaction - Molecular and Immunological Basis for Disease Management

View full text Add to dashboard Cite

show abstract

“…More recently (2021), idecabtagene vicleucel (Abecma ® , Bristol Myers Squibb) has received FDA approval and is currently awaiting EMA approval. The first approval of CAR-T cells as a tool to fight cancer was the result of near 30 years of robust research [ 11 ], since the first report of chimeric combination of receptors and antibodies was published in 1989 [ 12 ]. CAR19 T-cell therapy has been rapidly adopted for the treatment of several B-cell malignancies [ 13 ].…”

mentioning

confidence: 99%

The hospital exemption pathway for the approval of advanced therapy medicinal products: an underused opportunity? The case of the CAR-T ARI-0001

Trias

Juan

Urbano-Ispizúa

et al. 2022

Bone Marrow Transplant

View full text Add to dashboard Cite

In February 2021, the ‘Advanced Therapy Medicinal Product’ (ATMP) ARI-0001 (CART19-BE-01), developed at Hospital Clínic de Barcelona (Spain), received authorization from the Spanish Agency of Medicines and Medical Devices (AEMPS) under the ‘hospital exemption’ (HE) approval pathway for the treatment of patients aged >25 years with relapsed/refractory (RR) acute lymphoblastic leukemia (ALL). The HE pathway foreseen by the European Regulation establishing the legal framework for ATMPs intended to be placed on the market in the EU, allows access to ATMPs prepared on a non-routine basis, according to quality standards, like a custom-made product for an individual patient. Its use is limited to the same Member State where it was developed, in a hospital under the responsibility of a medical practitioner. HE-ATMPs must comply with national traceability and pharmacovigilance requirements and specific quality standards. HE offers an opportunity to develop ATMPs in close contact with clinical practice, with the quality and rapid access needed by patients and at a lower cost compared to regular market authorization. However, many barriers need to be overcome. Here we discuss relevant aspects of the development and authorization of ARI-0001 in the context of the heterogeneous frame of the European Regulation implementation across the Member States.

show abstract

Cancer vaccines: past, present and future; a review article

et al. 2022

View full text Add to dashboard Cite

Immunotherapy and vaccines have revolutionized disease treatment and prevention. Vaccines against infectious diseases have been in use for several decades. In contrast, only few cancer vaccines have been approved for human use. These include preventative vaccines against infectious agents associated with cancers, and therapeutic vaccines used as immunotherapy agents to treat cancers. Challenges in developing cancer vaccines include heterogeneity within and between cancer types, screening and identification of appropriate tumour-specific antigens, and the choice of vaccine delivery platforms. Recent advances in all of these areas and the lessons learnt from COVID-19 vaccines have significantly boosted interest in cancer vaccines. Further advances in these areas are expected to facilitate development of effective novel cancer vaccines. In this review, we aim to discuss the past, the present, and the future of cancer vaccines.

show abstract

A novel immunotherapy — the history of CAR T-cell therapy

Cited by 4 publications

References 30 publications

Immune System Modulations in Cancer Treatment: Nanoparticles in Immunotherapy

Immune System Modulations in Cancer Treatment: Nanoparticles in Immunotherapy

The hospital exemption pathway for the approval of advanced therapy medicinal products: an underused opportunity? The case of the CAR-T ARI-0001

Cancer vaccines: past, present and future; a review article

Contact Info

Product

Resources

About